2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
January 13, 2021
Video
Yi Lin, MD, PhD, discusses CAR T-cell therapy–related toxicities in multiple myeloma.
January 13, 2021
Video
Rafael Fonseca, MD, discusses the emergence of minimal residual disease in multiple myeloma.
January 08, 2021
Video
Shaji K. Kumar, MD, discusses sequencing selinexor-based combinations in relapsed/refractory multiple myeloma.
January 08, 2021
Article
Brexucabtagene autoleucel induced durable response in patients with relapsed/refractory mantle cell lymphoma, according to findings from the phase 2 ZUMA-2 trial, leading to an FDA approval for use in this patient population on July 24, 2020.
January 06, 2021
Video
Tanios S. Bekaii-Saab, MD, FACP, discusses incorporating potential mechanisms of resistance into treatment selection in hepatocellular carcinoma.
January 05, 2021
Video
Sikander Ailawadhi, MD, discusses the integration of selinexor into the treatment landscape of relapsed/refractory multiple myeloma.
January 05, 2021
Video
Yi Lin, MD, PhD, discusses the characteristics of patients who were included in the CRB-401 study examining the CAR T-cell product idecabtagene vicleucel in multiple myeloma.
December 30, 2020
Article
Alex A. Adjei, MD, PhD, discusses frontline treatment options for patients with advanced non–small cell lung cancer, as well as some of the nuances of selecting the optimal therapy.
December 21, 2020
Article
Matthew P. Goetz, MD, discusses ongoing research in the setting of ESR1-mutant, ER–positive, HER2-negative metastatic breast cancer.
December 20, 2020
Article
Rami Manochakian, MD, discusses the role of osimertinib in patients with EGFR-mutated NSCLC, strategies for treatment following progression on the third-generation TKI, and ongoing research efforts to further improve care.
December 18, 2020
Article
Javier L. Munoz, MD, discusses the nuances of choosing treatment options for patients with CLL in the frontline and relapsed/refractory settings, as well as novel therapeutic strategies on the horizon.
December 09, 2020
Article
December 9, 2020 — The BCMA-targeted antibody-drug conjugate MEDI2228 showed promising clinical efficacy in patients with relapsed/refractory multiple myeloma, with triple-refractory disease experiencing maintained responses.
November 19, 2020
Video
Tanios S. Bekaii-Saab, MD, FACP, discusses improved sequencing strategies in hepatocellular carcinoma.
November 10, 2020
Video
Daniel H. Ahn, DO, discusses the role of checkpoint inhibitor therapy in patients with microsatellite instability–high colorectal cancer who harbor an NTRK fusion.
November 04, 2020
Video
Tanios S. Bekaii-Saab, MD, FACP, discusses the future of telemedicine in colorectal cancer.
October 30, 2020
Video
Daniel H. Ahn, DO, discusses the identification of NTRK alterations in colorectal cancer.
October 27, 2020
Video
Daniel H. Ahn, DO, discusses the significance of the phase 3 KEYNOTE-177 trial in patients with microsatellite instability–high metastatic colorectal cancer.
October 23, 2020
Video
Daniel H. Ahn, DO, discusses the evolution of targetable alterations in colorectal cancer.
October 21, 2020
Video
Thorvardur Halfdanarson, MD, discusses the evolving role of immunotherapy in colorectal cancer.
October 14, 2020
Video
Tanios S. Bekaii-Saab, MD, FACP, discusses the emergence of targeted therapy in colorectal cancer.